Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction
- Resource Type
- Authors
- Emad S Mansour; Nesreen Ali; Mai Mehanna; Sarah Youssef; Seham Gohar; Sherine Salem; Elaine Coustan-Smith; Iman Sidhom; Gaston K. Rivera; Sonya Soliman; Khaled Shaaban; Wafaa M. Rashed; Raul C. Ribeiro; Dina Yassin
- Source
- Blood
- Subject
- Male
medicine.medical_specialty
Neoplasm, Residual
medicine.drug_class
Clinical Trials and Observations
medicine.medical_treatment
Immunology
Biochemistry
Gastroenterology
Antimetabolite
Internal medicine
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Antineoplastic Combined Chemotherapy Protocols
Medicine
Humans
Cumulative incidence
Child
Chemotherapy
business.industry
Remission Induction
Infant
Cell Biology
Hematology
medicine.disease
Minimal residual disease
Confidence interval
Regimen
Leukemia
medicine.anatomical_structure
Child, Preschool
Female
Bone marrow
business
- Language
- ISSN
- 1528-0020
Legacy data show that ∼40% of children with acute lymphoblastic leukemia (ALL) were cured with limited antimetabolite-based chemotherapy regimens. However, identifying patients with very-low-risk (VLR) ALL remains imprecise. Patients selected based on a combination of presenting features and a minimal residual disease (MRD) level